Clinical trial discovery in plain English. Data sourced from ClinicalTrials.gov.

About Browse conditions ClinicalTrials.gov ↗

Stella is not a medical provider and does not give medical advice. AI-generated summaries are for informational purposes only. Always consult your doctor before making any healthcare decisions.

A Cohort Study on ctDNA MRD in Neoadjuvant Therapy for Pancreatic Cancer — Stella

Home/Borderline Resectable Pancreatic Adenocarcinoma/A Cohort Study on ctDNA MRD in Neoadjuvant Therapy for Pancreatic Cancer

View on ClinicalTrials.gov

Recruiting

Back to Borderline Resectable Pancreatic Adenocarcinoma trials

A Cohort Study on ctDNA MRD in Neoadjuvant Therapy for Pancreatic Cancer

Trial locations(2 sites)

China

Ruijin Hospital Affiliated to Shanghai Jiaotong University School of Medicine, Shanghai

Ruijin hospital, Shanghai

Key details

Sponsor

Ruijin Hospital

Enrollment target

~119 participants

Started

May 2025

Primary completion

May 2026

Age range

18 Years – 75 Years

Last updated July 2025

Interested in joining?

Tell us you're interested and we'll help connect you with the research team. We'll never share your email without your permission.

Your name

Email address

Stella acts as an intermediary. Researcher contact info is never exposed.

Follow this trial

Get notified in plain English when this trial's status changes. No account required.